Production (Stage)
D
Actuate Therapeutics, Inc. ACTU
$10.33 $0.232.28% NASDAQ
Recommendation
Prev Close
$10.33
Volume
46,719
Avg Vol (90D)
44,163
Market Cap
$202.67M
Dividend & Yield
--
52-Week Range
$5.51 - $11.73
P/E (TTM)
--
EPS (TTM)
-$5.41
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline ...
5/22/2025 - GuruFocus
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline ...
5/22/2025 - GuruFocus
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
5/22/2025 - Globe Newswire
Actuate Therapeutics (NASDAQ:ACTU) vs. Shuttle Pharmaceuticals (NASDAQ:SHPH) Financial Survey
5/12/2025 - Ticker Report
Actuate Therapeutics (ACTU) to Host Key Opinion Leader Event at 2025 ASCO Meeting ACTU Stock News
5/7/2025 - GuruFocus
Actuate Therapeutics to host KOL event on Phase 2 elraglusib data
5/7/2025 - The Fly
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic ...
5/7/2025 - GuruFocus
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
5/7/2025 - Globe Newswire
Actuate Therapeutics announces elraglusib combination met primary endpoints
5/6/2025 - TipRanks Financial Blog
Actuate Therapeutics announces elraglusib combination met primary endpoints
5/6/2025 - The Fly
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 ...
5/6/2025 - GuruFocus
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
5/6/2025 - Globe Newswire
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
4/30/2025 - GuruFocus
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
4/30/2025 - Globe Newswire
Craig Hallum Begins Coverage on Actuate Therapeutics (NASDAQ:ACTU)
4/24/2025 - MarketBeat
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
4/23/2025 - Globe Newswire
Actuate Therapeutics (ACTU) Receives Buy Rating with Positive Phase II Study Outlook ACTU ...
4/22/2025 - GuruFocus
Craig-Hallum bullish on Actuate Therapeutics, initiates with a Buy
4/22/2025 - The Fly
Actuate Therapeutics initiated with bullish view at Craig-Hallum
4/22/2025 - The Fly
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
4/17/2025 - Globe Newswire
Actuate Therapeutics (NASDAQ:ACTU) Trading 6% Higher - Still a Buy?
4/12/2025 - MarketBeat
Actuate Therapeutics files to sell 3.9M shares of common stock for holders
3/28/2025 - The Fly
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
3/27/2025 - Business Wire
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer
3/26/2025 - SeekingAlpha
Actuate Therapeutics (NASDAQ:ACTU) Coverage Initiated at HC Wainwright
3/20/2025 - Zolmax
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$23.75M
Net Income (TTM)
-$25.31M
Balance Sheet
Total Assets (Q)
$4.48M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$9.57M
Book Value Per Share (Q)
-$0.2605
Cash Flow
Cash from Operations (TTM)
-$21.21M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$23.03M
Net Change in Cash (TTM)
$1.82M
Filings
Filing Date
Thursday, May 15, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Sep 22 and 26 (est)
Price History
Loading...
Beta
--
7-Day Total Return
5.84%
30-Day Total Return
34.86%
60-Day Total Return
42.68%
90-Day Total Return
21.82%
Year to Date Total Return
29.77%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Sep 25, 2024 - $5.51
52-week High
Jan 23, 2025 - $11.73
Valuation
Market Cap
$202.67M - Micro Cap
Enterprise Value
$198.78M
Price/Sales (TTM)
--
Price/Book (Q)
-39.65
Dividends and Shares
Shares Outstanding
19.50M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
actuatetherapeutics.com
Phone Number
817 887 8455
Address
1751 River Run
Fort Worth, TX 76107
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed